改良脑损伤指南1类患者的特征与院内结局
结果显示出血进展罕见(3.6%),无患者接受神经外科干预,院内死亡率0.7%;额外25例院前服用81mg阿司匹林的患者同样无神经外科干预或死亡。
要点
- mBIG 1类患者出血进展率3.6%,无需神经外科干预。
- 院前服用低剂量阿司匹林者出血进展率4.0%,仍无神经外科干预。
- mBIG 1类患者院内死亡率0.7%,75.2%出院回家。
核心结论
- mBIG 1类患者出血进展罕见,即使院前服用低剂量阿司匹林亦无神经外科干预或死亡。
主要发现
- CT扫描平均2.28次(SD 0.03),硬膜下血肿40.6%、脑实质出血5.9%、蛛网膜下腔出血41.6%,多发出血11.9%。
- 出血进展11例(3.6%),无神经外科干预,平均ISS 13.12(SD 7.04),住院时间中位数1.01天(IQR 0.37-4.56),75.2%出院回家,24.1%转康复,0.7%院内死亡。
- 25例ASA81患者无神经外科干预或死亡,1例(4.0%)出血进展但仍符合mBIG 1;与mBIG 1队列相比,ASA81组年龄更大(p < 0.001),其他变量无差异。
- 合并队列按出血进展分层(n=12),进展组住院时间更长(p = 0.017)且出院回家比例更低(p = 0.001)。
临床怎么用
- mBIG 1类患者可安全地减少重复CT和神经外科会诊,但需关注出血进展风险。
- 院前服用低剂量阿司匹林并非mBIG 1分诊的排除标准,但需更多数据验证。
局限性
- 回顾性单中心设计,样本量有限,低剂量阿司匹林亚组仅25例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Brain Injury Guidelines (BIG) were modified in 2020 to improve efficiency and safety in triage decision-making. The aim of this study was to present characteristics and in-hospital outcomes of patients classified under category 1 of the modified BIG (mBIG 1). METHODS: A retrospective review of patients presenting with acute traumatic brain injury (TBI) to a level 1 trauma center between 2019 and 2023 was performed. Patients meeting clinical and radiographic criteria for mBIG 1 were identified. An additional cohort of patients was identified who were taking 81 mg of aspirin once daily (ASA81) before the hospital, but who otherwise met mBIG 1 criteria. Summary statistics and univariate analyses were performed. RESULTS: Three hundred three patients were identified and classified as mBIG 1. The mean patient age was 54.45 (SD 1.17) years and 41.3% were female. There were 144 patients (47.5%) who transferred from an outside hospital. The median admission Glasgow Coma Scale score was 15 (interquartile range [IQR] 15-15). Patients underwent an average of 2.28 (SD 0.03) CT scans. There were 123 (40.6%), 18 (5.9%), and 126 (41.6%) patients with subdural hematoma, intraparenchymal hemorrhage, and subarachnoid hemorrhage, respectively, with 36 patients (11.9%) presenting with multiple hemorrhages. Eleven patients (3.6%) experienced hemorrhage progression. No patient underwent neurosurgical intervention. The mean Injury Severity Score was 13.12 (SD 7.04). The median hospital length of stay (LOS) was 1.01 (IQR 0.37-4.56) days, 75.2% of patients were discharged home, 24.1% were discharged to rehabilitation, and 0.7% died in the hospital. An additional 25 patients were identified who were taking ASA81 prehospital, but otherwise met mBIG 1 criteria. None of these patients underwent neurosurgical intervention and there were no in-hospital deaths. One patient (4.0%) taking ASA81 experienced progression of their hemorrhage but still met mBIG 1 criteria. When compared to the mBIG 1 cohort, the aspirin cohort was significantly older (p < 0.001), but otherwise showed no differences in demographic, clinical, or radiographic variables. The combined mBIG 1 + aspirin cohort was stratified by hemorrhage progression (n = 12). Hospital LOS was significantly greater in the progression cohort (p = 0.017) and fewer patients were discharged home (p = 0.001). There was no difference in age, hypertension, admission mean arterial pressure, platelet count, international normalized ratio, partial thromboplastin time, hemorrhage pattern, and aspirin use between the groups. CONCLUSIONS: Hemorrhage progression was rare, including cases in which patients were receiving prehospital low-dose aspirin therapy. More data are needed that evaluate the role of low-dose aspirin in the triage of patients with mild TBI.
引用
- Kim KT, Yarmoska SK, Lomangino C, et al. Characteristics and in-hospital outcomes of patients presenting to a level 1 trauma center classified under the modified Brain Injury Guidelines. J Neurosurg. 2025. PMID: 41072050. doi:10.3171/2025.6.JNS25342
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。